-
Mashup Score: 0
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. on LinkedIn: SGO 2023 GOG 3026 Phase II Trial of Letrozole + Ribociclib in Women With… - 11 month(s) ago
The results of @GOG 3026 presented at #SGO2023. #Ribociclib & #Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer. From…
Source: www.linkedin.comCategories: Latest Headlines, Oncologists1Tweet-
The results of @GOG 3026 presented at #SGO2023. #Ribociclib & #Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer. From @VuMedi. @kisqali_us #clinicaltrial #ovariancancer #oncology #SGOmtg #gyncsm The GOG Founda…https://t.co/WbDTstiRBI https://t.co/Uu5Vk4A1uJ
-
-
Mashup Score: 1Join me! | Key Findings and Expert Recommendations in Gynecologic Malignancies: Independent 2023 Conference/Congress Coverage - 48714 - 12 month(s) ago
Expert slides, podcasts, commentaries, and more on emerging data in gynecologic cancers from key 2023 conferences, from Clinical Care Options (CCO)
Source: clinicaloptions.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Expert Insight on New Data From #SGO2023 Informing Treatment for #Endometrialcancer, #CervicalCancer, & #ovariancancer from @CCO_LLC. #gyncsm #NRGatSGO #SGOMtg #clinicaltrial #oncology @NRGonc @GOG @LDuska @KEYTRUDA @jemperli @kisqali_us https://t.co/03HXPTHLyM
-
-
Mashup Score: 0
By The ASCO Post Staff Posted: 3/30/2023 10:54:00 AM Last Updated: 3/30/2023 1:57:12 PM Researchers have found that concurrent treatment with gemcitabine as well as cisplatin and intensity-modulated radiation therapy may effectively increase the pathologic complete response rates in patients with locally…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
More on @NRGonc trial @GOG 279 at #SGOmtg!  #Gemcitabine Plus #Cisplatin and #IMRT Produces Complete Responses in #vulvarcancer. From @ASCOPost #gyncsm #NRGatSGO #SGO2023 #clinicaltrial #oncology https://t.co/AIk3evaoQA
-
-
Mashup Score: 0The Role of the Gynecologic Oncologist - 1 year(s) ago
In this video, Stephanie V. Blank, MD, and Warner K. Huh, MD, discuss the evolving role of the gynecologic oncologist, including the use of chemotherapy, benign surgery, and the management of patients with placenta accrete spectrum. They also discussed these topics during an interactive session at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer titled “The Future…
Source: Consultant360Categories: General Medicine News, Latest HeadlinesTweet-
Watch Stephanie V. Blank, MD, and Warner K. Huh, MD, discuss the evolving role of the gynecologic oncologist, including the use of chemotherapy, benign surgery, and the management of patients with placenta accrete spectrum. https://t.co/cwznJIhBcA #C360 #SGO2023 @SGO_org
-
-
Mashup Score: 0
Patients with advanced endometrial cancer experience early responses to lenvatinib plus pembrolizumab in both patients who were mismatch repair proficient and all-comers.
Source: Cancer NetworkCategories: Hem/Oncs, Latest HeadlinesTweet-
#Lenvatinib & #pembrolizumab Combo Yields Robust, Enduring Responses in #endometrialcancer. From @CancerNetwrk #gyncsm #SGOMtg @Lenvima_HCP @KEYTRUDA #SGO2023 #clinicaltrial #KEYNOTE https://t.co/mT3fpHEIBp
-
-
Mashup Score: 0Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer - 1 year(s) ago
Botensilimab in combination with balstilimab induced durable responses in patients with resistant/refractory ovarian cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Botensilimab in combination with balstilimab induced durable responses in patients with resistant/refractory ovarian cancer. #SGO2023 #ovca https://t.co/IFkEBkzLNI https://t.co/oKCqGj2xHR
-
-
Mashup Score: 0Toripalimab Plus Bevacizumab/Chemotherapy Generates Responses in Refractory, Recurrent, or Metastatic Cervical Cancer - 1 year(s) ago
The combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to preliminary data from a phase 2 trial, the combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer. @MGHCancerCenter #sgo2023 #ovca https://t.co/ViDMGvVAEU https://t.co/LWIv4i2gvW
-
-
Mashup Score: 1Post-Hoc Analysis Shows PFS Benefit of Maintenance Niraparib Not Affected by Dose Modifications in Ovarian Cancer - 1 year(s) ago
The use of an individualized starting dose and dose modifications due to treatment-emergent adverse effects did not impact the efficacy of maintenance niraparib in patients with newly diagnosed ovarian cancer, irrespective of BRCA mutation status.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The use of an individualized starting dose and dose modifications due to treatment-emergent AE did not impact the efficacy of maintenance niraparib in pts w/ newly diagnosed ovarian cancer, irrespective of BRCA mutation status. #ovca #SGO2023 https://t.co/srmfhAvL0e https://t.co/XUyYPhFuHb
-
-
Mashup Score: 0Neoadjuvant Durvalumab/Tremelimumab Plus Chemo Meets PFS End Point in Advanced Ovarian Cancer - 1 year(s) ago
Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer. #SGO2023 #ovca https://t.co/oNOiPSZevp
-
A look back on #SGO2023, where experts discussed radiotherapy, cryocompression, recovery trackers, and more. Check out interviews detailing these developments in the gynecologic cancer space with the link below! 👇 #gyncsm | @SGO_org https://t.co/6Ko1VPS6Wg https://t.co/3OZg1KTMDb